Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

PURPOSE: Locally advanced or metastatic urothelial carcinoma is an incurable disease with limited treatment options, especially for patients who were previously treated with platinum and anti–programmed death 1 or anti–programmed death ligand 1 (PD-1/L1) therapy. Enfortumab vedotin is an antibody–dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenberg, Jonathan E., O’Donnell, Peter H., Balar, Arjun V., McGregor, Bradley A., Heath, Elisabeth I., Yu, Evan Y., Galsky, Matthew D., Hahn, Noah M., Gartner, Elaina M., Pinelli, Juan M., Liang, Shang-Ying, Melhem-Bertrandt, Amal, Petrylak, Daniel P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
RAPID COMMUNICATION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784850/
https://www.ncbi.nlm.nih.gov/pubmed/31356140
http://dx.doi.org/10.1200/JCO.19.01140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784850/
https://www.ncbi.nlm.nih.gov/pubmed/31356140
http://dx.doi.org/10.1200/JCO.19.01140

Ejemplares similares